A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Summary
This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Age ≥ 18 years * MF: * Intermediate-1 or higher risk PMF, post-PV MF, or post-ET MF with evidence of minimum burden of disease based on splenomegaly, and for the monotherapy cohort, participants must have been previously treated with at least 1 JAK inhibitor for ≥ 12 weeks and resistant, refractory, intolerant to, or have lost response to JAK inhibitor treatment. * For the MF SubOpt R cohort: Therapeutic regimen prior to enrollment as defined in the protocol and unlikely to benefit from further monotherapy in the opinion of the investigator. * PV: Confirmed diagnosi…
Interventions
- DrugINCB160058
Oral; Tablet
- DrugStandard disease-directed therapy
A standard disease-directed therapy will be administered according to Prescribing Information/SmPC.
Locations (30)
- The University of Alabama At BirminghamBirmingham, Alabama
- Stanford UniversityPalo Alto, California
- Moffitt Cancer CenterTampa, Florida
- Northwestern UniversityChicago, Illinois
- The University of Kansas Cancer Center Kucc University of Kansas Clinical Research CenterFairway, Kansas
- University of MichiganAnn Arbor, Michigan